Keep pulling the thread on Prashant Warier.
Prashant Warier predicts that AI will become the primary interface for patient care in primary care settings within the next 5 to 10 years.
Qure.ai has received 26 clearances from the U.S. Food and Drug Administration (FDA) for its products.
In 2021, the World Health Organization (WHO) endorsed Qure.ai's algorithm for autonomous interpretation of chest X-rays to detect tuberculosis.
Qure.ai's tuberculosis screening algorithm is used across approximately 70 to 75 countries to screen more than 15 million patients annually.
Clinical studies have demonstrated that Qure.ai's platform can enable a lung cancer diagnosis more than 60 days earlier than standard methods.
In the CREATE study, 54 out of 100 patients identified as high-risk by Qure.ai's Lung Nodule Malignancy Risk Score were subsequently confirmed to have lung cancer via a CT scan.
The CREATE study demonstrated that Qure.ai's Lung Nodule Malignancy Risk Score has a sensitivity of over 95% for detecting lung cancer.
Qure.ai has built a database of more than 1.5 billion medical images to train its AI algorithms.
Qure.ai has 65 of its AI-detected findings cleared for use in Europe via CE marking.
Qure.ai's products are cleared for use in more than 105 countries.
Qure.ai's lung cancer pathway product is currently used by approximately 700 to 800 medical centers worldwide.
Qure.ai's platform can detect 16 different kinds of fractures on musculoskeletal X-rays.